Cardio-Metabolic

Cardio-Metabolic includes companies targeting cardiovascular disease, obesity, diabetes, lipid disorders, and related metabolic conditions. This page highlights businesses exposed to some of the largest and most competitive treatment categories in biotech and pharma.

Why watch Cardio-Metabolic

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Cardio-Metabolic news

The latest feed items from companies currently grouped under Cardio-Metabolic.

1. 01
   2026-10-06 11:05 EST

   VKTXViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

   Source: Viking Therapeutics

2. 02
   2026-10-05 20:05 EST

   ALGSAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

   Source: Aligos Therapeutics

3. 03
   2026-10-02 20:30 EST

   MLYSMineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

   Source: Mineralys Therapeutics

4. 04
   2026-10-02 20:01 EST

   NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   Source: NewAmsterdam Pharma

5. 05
   2026-10-01 20:31 EST

   SGMTSagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

   Source: Sagimet Biosciences

6. 06
   2026-10-01 20:05 EST

   MLYSMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

   Source: Mineralys Therapeutics

7. 07
   2026-09-30 10:19 EST

   SGMTSagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

   Source: Sagimet Biosciences

8. 08
   2026-09-30 10:00 EST

   SGMTSagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

   Source: Sagimet Biosciences

9. 09
   2026-09-29 20:30 EST

   CVRXCVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

   Source: CVRx

10. 10
    2026-09-29 20:05 EST

    MLYSMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Source: Mineralys Therapeutics

11. 11
    2026-09-29 12:00 EST

    NAMSNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

    Source: NewAmsterdam Pharma

12. 12
    2026-09-29 00:00 EST

    BLTEBelite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

    Source: Belite Bio

13. 13
    2026-09-28 20:30 EST

    VKTXViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

    Source: Viking Therapeutics

14. 14
    2026-09-28 11:00 EST

    SGMTSagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

    Source: Sagimet Biosciences

15. 15
    2026-09-24 20:05 EST

    MLYSMineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

    Source: Mineralys Therapeutics

16. 16
    2026-09-24 12:00 EST

    MISTMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

    Source: Milestone Pharmaceuticals Inc.

17. 17
    2026-09-24 11:05 EST

    VKTXViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

    Source: Viking Therapeutics

18. 18
    2026-09-23 20:32 EST

    VKTXViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes

    Source: Viking Therapeutics

19. 19
    2026-09-23 20:05 EST

    MLYSMineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

    Source: Mineralys Therapeutics

20. 20
    2026-09-23 12:00 EST

    ALTAltimmune to Participate in Stifel Cardiometabolic Forum

    Source: Altimmune

Companies in Cardio-Metabolic

35 companies tagged with Cardio-Metabolic.

Frequently Asked Questions